Erika Anders
Family · Columbus, GANPI 1871244624
Payments from drug & device makers
Across 117 payments — averaging $19.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$397
- Myriad Genetic Laboratories, Inc.$370
- Endo Pharmaceuticals Inc.$218
- Axonics, Inc.$170
- Sumitomo Pharma America, Inc.$145
- Merck$123
- plus $832 from 19 others
What the payments were for
- Food & beverage$2,254100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer | 23 | $397 |
| Myriad Genetic Laboratories, Inc. | 19 | $370 |
| Endo Pharmaceuticals Inc. | 11 | $218 |
| Axonics, Inc. | 8 | $170 |
| Sumitomo Pharma America, Inc. | 9 | $145 |
| Merck | 5 | $123 |
| Johnson & Johnson(2 entities) | 4 | $94 |
| AbbVie | 5 | $85 |
| Tolmar, Inc. | 3 | $78 |
| Teleflex LLC | 3 | $64 |
| 180 Medical, Inc. | 4 | $64 |
| Olympus America Inc. | 3 | $48 |
| Medtronic | 3 | $45 |
| Astellas Pharma US Inc | 2 | $45 |
| Progenics Pharmaceuticals, Inc. | 2 | $39 |
| Laborie Medical Technologies Corp. | 2 | $38 |
| Bayer | 2 | $38 |
| Boston Scientific | 2 | $34 |
| Henry Schein, Inc. | 1 | $32 |
| Sun Pharmaceutical Industries Inc. | 1 | $30 |
| Dendreon Pharmaceuticals LLC | 1 | $27 |
| Endo USA, Inc. | 1 | $23 |
| Coloplast | 1 | $19 |
| Kowa Pharmaceuticals America, Inc. | 1 | $15 |
| Urovant Sciences Inc | 1 | $12 |
How this compares
$2,254 in reported general payments places this provider in the 80th percentile of 6,258 family providers in Georgia.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| GemtesaVibegron | 18 | $20,668 |
| MyrbetriqMirabegron | 13 | $10,262 |
| Testosterone | 19 | $5,927 |
| Testosterone Cypionate | 66 | $4,671 |
| Tamsulosin Hcl | 274 | $3,697 |
| Solifenacin Succinate | 22 | $1,520 |
| Finasteride | 125 | $1,468 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 21 | $913 |
| Oxybutynin Chloride | 36 | $587 |
| Alfuzosin Hcl ErAlfuzosin Hcl | 19 | $423 |
| Doxycycline Monohydrate | 24 | $381 |
| Tadalafil | 11 | $380 |
| Ciprofloxacin Hcl | 86 | $324 |
| Oxybutynin Chloride ErOxybutynin Chloride | 11 | $126 |
| Levofloxacin | 23 | $96 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Sumitomo Pharma America, Inc.Gemtesa | $145 | $20,66818 claims |
| Astellas Pharma US IncMyrbetriq | $45 | $10,26213 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 6,258 family providers in Georgia.
Other family in Columbus
- Allie McAllisterMarietta$299K
- Tonita WashingtonLawrenceville$153K
- Erin HenryLawrenceville$135K
- Trisha RomanPeachtree City$134K
- Lori ReedMarietta$106K
- Julia BranchCumming$102K
- Hannah BanachWaycross$85K
- Morgan GroothandEvans$81K
- Anna Carolina WrightLilburn$69K
- Jessica FeehanCanton$51K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.